Exclusive: Pfizer, Ginkgo sign R&D deal worth up to $331M to develop RNA drugs - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
In its latest Big Pharma deal, Ginkgo Bioworks will work with Pfizer to develop new RNA drugs, the Boston-based synthetic biology startup exclusively told Endpoints News. The two aren’t disclosing many specifics about the collaboration, but the deal will focu…